For the SOLAR-1 and SANDPIPER trials, which did not report complete PFS data, we derived the results by synthesizing PFS data from patients with and without PIK3CA mutations confirmed through tumor tissue testing. This evidence concerns the gene PIK3CA and neoplasm.